Blockbuster drugs

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising.

BeiGene still bleeding red ink despite blockbuster drug

The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
BGNE.US 6160.HK 688235.SHG

Recent Articles

RELATED ARTICLES

  1. The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year.
    BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
  2. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Innovent Bio hopes for plus-sized profits from obesity drug
    1801.HK
  5. Novel drugs lift Sino Biopharm earnings, easing price-cap pain
    1177.HK
  6. Junshi narrows its losses but delivers no cure for share price woes
    1877.HK 688180.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva